Clinical trial
A Randomized, Double Blind, Crossover, Placebo- and Active Controlled Dose Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With COPD
NCT02182674 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double Blind, Crossover, Placebo- and Active Controlled Dose Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With COPD
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2000
- Completion date
- Not reported
- Enrollment
- 66 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.